Skip to main content
    C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.51
    -0.02 (-3.73%)

    Market Cap: $81.21M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/40)
    Avg Surprise
    -8.47%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.22
    Range-$0.28 - -$0.19
    9 analysts
    Revenue Consensus
    $17.43M
    Range$15.58M - $19.84M
    8 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.20
    Range-$0.20 - -$0.20
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.21+4.8%
    60d ago-$0.26+23.1%
    30d ago-$0.26+23.1%
    7d ago-$0.26+23.1%
    Current-$0.20
    Revenue Consensus
    $18.49M
    Range$16.40M - $20.50M
    4 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-253.40%Operating Margin-271.10%
    ROE-275.20%ROIC-144.80%
    Financial Health
    Debt/Equity2.08xInterest Coverage-11.05x
    Current Ratio1.51xQuick Ratio1.45x
    Trading Statistics
    Beta1.05Avg Volume2.41M
    52-Week High$2.6252-Week Low$0.50

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 51.4% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 27.7, below 30, the oversold line.

    Moving Averages

    SMA 10$0.68
    SMA 20$0.83
    SMA 50$1.04
    SMA 200$1.46
    EMA 10$0.66
    EMA 20$0.78
    EMA 50$0.98
    EMA 200$1.29

    MACD

    Line: -0.15Signal: -0.12Hist: -0.03

    ADX

    ADX: 31.8+DI: 14.9-DI: 41.6

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down100.0
    PSAR$0.85

    Bollinger Bands

    Upper Band$1.23
    Lower Band$0.43
    %B Position9565%(Upper)
    Band Width0.09

    RSI (14-Day)

    Oversold
    27.7

    Momentum Oscillators

    Stoch %K3.8
    Stoch %D3.7
    Williams %R-96.1
    ROC (10d)-32.5%
    Momentum-0.24
    CCI (20d)-141.4
    MFI (14d)21.4

    Volatility Measures

    ATR (14d)$0.09(17.5%)
    StdDev (20d)0.20
    Hist Vol144.2%(High)

    Volume Flow

    VWAP$0.50
    OBV30.3M
    AD Line-17.1M
    CMF (20d)-0.225

    Volume Metrics

    Avg Vol (20d)2.4M
    Vol Ratio1.5x
    VWMA (20d)$0.73

    Pivot Points

    R3$0.58
    R2$0.56
    R1$0.54
    Pivot Point$0.52
    S1$0.51
    S2$0.49
    S3$0.47

    Advanced Oscillators

    TSI-34.86
    Ultimate Osc36.5
    KST-351.33

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about CHRS

    News

    CHRS Valuation

    GNG's valuation label for CHRS is Undervalued. It trades at 41.1x forward earnings.

    Forward P/E
    41.1x
    P/B
    3.1x
    CHRS valuation multiples

    CHRS Profitability: Margins, ROIC and FCF

    Coherus BioSciences (CHRS) has a gross margin of 69.8%, an operating margin of -271.1% and a net margin of -253.4%. It posts -144.8% ROIC and a -323.9% FCF margin.

    Gross margin
    69.8%
    Operating margin
    -271.1%
    Net margin
    -253.4%
    ROIC
    -144.8%
    ROE
    -275.2%
    FCF margin
    -323.9%
    CHRS financial statements

    Coherus BioSciences Competitors

    The companies most similar to Coherus BioSciences (CHRS) include Heron Therapeuti, TuHURA Biosciences and Seer.

    Sector: Healthcare

    Companies most similar to Coherus BioSciences

    CHRS Analyst Ratings

    Coherus BioSciences (CHRS) has a Buy consensus from 6 analysts: 5 Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0
    CHRS stock forecast

    CHRS Bull Case vs Bear Case

    Bull case

    • CHRS grew quarterly revenue 23.4% year over year.
    • 83.3% of CHRS's analyst ratings are Buy or Strong Buy.

    Bear case

    • CHRS has a -253.4% net profit margin.
    • CHRS beat EPS estimates in 12.5% of its last 8 reported quarters.
    • CHRS has a debt-to-equity ratio of 2.1x.

    CHRS Earnings: Beat Rate and Next Report

    Coherus BioSciences (CHRS) beat the EPS estimate in 1 of the last 8 quarters (12.5%). Its next report is expected on Mar 8, 2027.

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -36.4%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.22
    CHRS earnings history

    CHRS Earnings Date

    CHRS reports Mar 8, 2027. The date is estimated.

    CHRS Earnings Call

    The latest CHRS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    See insider activity

    Updated Nov 9, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About CHRS

    When does CHRS report earnings?

    Coherus BioSciences Inc (CHRS) is expected to report earnings on Mar 8, 2027.

    Does CHRS pay dividends?

    Coherus BioSciences Inc (CHRS) does not currently pay a regular dividend.

    What is CHRS's market cap?

    Coherus BioSciences Inc (CHRS) has a market capitalization of $81.21M with a current stock price of $0.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.